The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma.

摘要: Introduction: Maintenance therapy after autologous transplantation is a standard of care in newly diagnosed myeloma. However, there no universal answer to the question which maintenance strategy should be pursued ASCT? Areas covered: We conducted MEDLINE search using medical subject headings 'multiple myeloma', 'autologous transplantation' and 'maintenance' identify available data from clinical trials on role different strategies for disease. Expert opinion: A large meta-analysis demonstrated that lenalidomide prolongs progression-free overall survival compared observation/placebo. Further confirmed increases rates high-quality responses one study improves outcomes regardless cytogenetic risk. Although can cause side effects associated with an increased risk second primary malignancies, its benefits outweigh mentioned risks. The proteasome inhibitors ixazomib bortezomib may partially overcome negative high-risk cytogenetics. Future will combine agents monoclonal antibodies during investigate whether minimal residual disease status guide duration.